THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and Adaptive Biotechnologies (ADPT) announced they will collaborate to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The companies will begin work immediately and finalize financial terms in the coming weeks.
Adaptive Biotechnologies will extend its high throughput platform to screen the genetic diversity of the B cell receptors from individuals that have recovered from COVID-19. This enables the identification of antibodies from survivors of COVID-19 to select those that neutralize SARS-CoV-2.
Copyright RTT News/dpa-AFX